STOCKHOLM -- The novel diabetes drug linagliptin (proposed trade name Ondero) may find a niche in treating patients with kidney problems, diabetologists suggested here.
In a phase III study of patients who couldn't take metformin because of the drug's GI side effects or renal impairment, linagliptin effectively reduced glycated hemoglobin and glucose compared with placebo, Anthony H. Barnett, MD, of the University of Birmingham, England, and colleagues found.
In a second study, renal impairment didn't reduce clearance of the DPP-4 inhibitor nor did the drug worsen renal impairment.
Thus, poor kidney function wouldn't require a dose adjustment, according to Ulrike Graefe-Mody, PhD, of Boehringer Ingelheim in Giberach, Germany, and colleagues.
Both company-sponsored studies were presented at the European Association for the Study of Diabetes meeting.